Releasing the brakes on cancer immunotherapy

New England Journal of Medicine

Volumn 373, Issue 16, 2015, Pages 1490-1492

  Ribas, Antoni ^a,b  

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MEDICAL INFORMATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPH NODES; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84944472689     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1510079     Document Type: Review

References (5)

1. McIntyre BW, Allison JP. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell 1983;34:739-46.
2. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-9.
3. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
4. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-9.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.